New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
11:34 EDTPTNNoble Financial says regulatory developments positive for Palatin Tech
Noble said Sprout Pharmaceuticals received FDA clarity for the re-submission of the flibanserine NDA for female sexual dysfunction, or FSD, which provides efficacy endpoints. The analyst said Palatin can now plan Phase III trials for FSD with "agreed upon" endpoints, and when combined with regulatory clarity, should increase interest from big Pharma. Shares are Buy rated with a $2.50 price target.
News For PTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
18:56 EDTPTNOn The Fly: After Hours Movers
HIGHER: Regulus Therapeutics (RGLS), up 8.7% after the company announced that it will present new preclinical data on RG-012 for kidney disease... Palatin Technologies (PTN), up 9.6% after director Robert deVeer Jr. buys 10,000 shares of common stock... Arena Pharmaceuticals (ARNA), up 4.7% after CEO Jack Lief announced his retirement and Harry Hixson was named interim CEO... DuPont (DD), up 5.9% after CEO and chair Ellen Kullman retires... Ruckus Wireless (RKUS), up 4.9% after joining the S&P 600... Starz (STRZA), up 10.1% after the LA Times reports that Lionsgate (LGF) is in advanced talks to merge with Starz. DOWN AFTER EARNINGS: Container Store (TCS), down 10.4%. ALSO LOWER: Sarepta Therapeutics (SRPT), down 3.8% after filing to sell $125M of common stock... Haemonetics (HAE), down 12.2% after lowering its fiscal 2016 outlook... Energy XXI (EXXI), down 8.3% after filing a $500M mixed securities shelf... Mallinckrodt (MNK), down 1.6% after announcing that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6.
18:05 EDTPTNPalatin director Robert deVeer Jr. buys 10K shares of common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use